货号:A164114
同义名:
AMG-073 hydrochloride; Cinacalcet (hydrochloride)
Cinacalcet hydrochloride (AMG-073 hydrochloride)是一种口服活性、别构激动剂Ca受体(CaR),用于治疗心血管疾病。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | CaSR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPS-2143 |
++++
Ca(2+) receptor, IC50: 43 nM |
98+% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Calcium-sensing receptor (CaSR), which belongs to the G protein-coupled receptor superfamily, is responsible for the regulation of systemic Ca2+ metabolism. Cinacalcet hydrochloride is a calcimimetic that allosterically increases the sensitivity and responsiveness of CaSR to Ca2+. It activates the wild-type CaSR signaling in cellular proliferation and PI hydrolysis assays with pEC50 values of 7.6 and 7.3, respectively[1]. When primary cultured human parathyroid cells were incubated with 0.5 mM extracellular Ca2+, cinacalcet hydrochloride from 0 – 1000 nM additionally suppressed the secretion of parathyroid hormone at a dose-dependent manner[2]. Cinacalcet hydrochloride at 30 – 1000 nM had no effect on osteoclastic formation or resorption in osteoclastic cells cultured in calcium-containing medium with the concentration of 1.6 or 6.1 mM[3]. Oral administration of primary hyperparathyroidism mice with 1 mg/g cinacalcet hydrochloride for 10 days led to significantly reduced levels of parathyroid and Ca in serum. The uptake of 5-Bromo-2’-deoxyuridine was also significantly decreased in mice following the administration of cinacalcet hydrochloride compared to the untreated ones[4]. |
| 作用机制 | Cinacalcet hydrochloride cooperates with Ca2+ to activate CaSR via interacting with its transmembrane domain[1]. |
| Concentration | Treated Time | Description | References | |
| T84 cells | 30 µM | 20 minutes | Cinacalcet pretreatment inhibited all 3 components of forskolin and cholera toxin-induced secretory I sc by ∼75%. | Transl Res. 2024 Jan;263:45-52. |
| MDCK cells | 30 µM | 20 minutes | Cinacalcet inhibited forskolin-induced cAMP elevation, and its effect was completely reversed by PDE inhibitor IBMX | Transl Res. 2024 Mar;265:17-25. |
| HEK293 cells | 10 nM | 20 minutes | Cinacalcet normalized the signaling responses of Gly195 mutant Gα11 protein, reducing the EC50 from 3.39 mM to 2.70 mM, which was indistinguishable from untreated WT cells. | JCI Insight. 2017 Oct 19;2(20):e96540. |
| T84 cells | 10 µM and 30 µM | 20 minutes | Cinacalcet significantly inhibited forskolin-induced Cl- secretion, primarily through indirect inhibition of CFTR-mediated Cl- secretion following activation of CaSR and downstream phospholipase C and phosphodiesterases. | JCI Insight. 2021 Feb 22;6(4):e146823. |
| FRT cells | 30 µM | 20 minutes | Cinacalcet did not affect CFTR-mediated Cl- conductance in FRT cells, indicating that its inhibitory effect is dependent on CaSR activation. | JCI Insight. 2021 Feb 22;6(4):e146823. |
| HBE cells | 30 µM | 20 minutes | Cinacalcet significantly inhibited CFTR-mediated Cl- secretion in HBE cells but had no significant effect on ENaC or CaCC activities. | JCI Insight. 2021 Feb 22;6(4):e146823. |
| HEK293 cells | 100 nM | 30 minutes | Cinacalcet rectified the abnormal intracellular calcium signaling of Ile555Thr CaSR protein, restoring its response to changes in extracellular calcium concentrations. | J Clin Endocrinol Metab. 2024 Jan 18;109(2):549-556. |
| MDCK cells | 10 µM | 6 days | Cinacalcet concentration-dependently reduced cyst growth in MDCK cells by up to 50% | Transl Res. 2024 Mar;265:17-25. |
| Human ADPKD cells | 3 µM | 6 days | Cinacalcet treatment inhibited forskolin-induced cyst enlargement in human ADPKD cells by 60% | Transl Res. 2024 Mar;265:17-25. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Intestinal closed loop models of cholera and traveler’s diarrhea | Intraperitoneal injection | 1 mg/kg, 10 mg/kg, and 30 mg/kg | Single dose, lasting 3 hours | Cinacalcet significantly reduced cholera toxin- and STa toxin-induced intestinal fluid accumulation, primarily through inhibition of CFTR-mediated secretion and stimulation of NHE3-mediated absorption. | JCI Insight. 2021 Feb 22;6(4):e146823. |
| Mice | ADPKD mouse model | Subcutaneous injection | 20 mg/kg/day | Once daily for 7 days | Cinacalcet treatment reduced renal cyst index in the ADPKD mouse model by 20% | Transl Res. 2024 Mar;265:17-25. |
| Mice | Gna11+/195G and Gna11195G/195G mice | Oral | 30 mg/kg | Single dose, monitored for 24 hours | Cinacalcet significantly reduced plasma calcium and PTH concentrations in Gna11+/195G and Gna11195G/195G mice, with plasma calcium significantly reduced between 2-6 hours after dose and PTH significantly reduced at 1 hour after dose, returning to baseline by 4-6 hours. | JCI Insight. 2017 Oct 19;2(20):e96540. |
| Mice | Wild type mice | 30 μM | 20 minutes | Cinacalcet pretreatment reduced forskolin-induced secretory Isc by 55%. | Transl Res. 2024 Jan;263:45-52. |
| Dose | Rat: 1 mg/kg - 10 mg/kg[5] (p.o.); 0.1 mg/kg - 10 mg/kg[1] (s.c.) Mice: 10 mg/kg - 100 mg/kg (p.o.) |
| Administration | p.o., s.c. |
| Pharmacokinetics |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01100723 | - | Completed | - | - | |
| NCT02464072 | Hyperparathyroidism, Secondary | Not Applicable | Active, not recruiting | July 2019 | Brazil ... 展开 >> University of Sao Paulo General Hospital Sao Paulo, SP, Brazil 收起 << |
| NCT01073462 | - | Completed | - | Austria ... 展开 >> Site Reference ID/Investigator# 27447 Graz, Austria, 8010 Site Reference ID/Investigator# 49182 Graz, Austria, 8020 Site Reference ID/Investigator# 27483 Graz, Austria, 80360 Site Reference ID/Investigator# 52742 Graz, Austria, 8052 Site Reference ID/Investigator# 27487 Innsbruck, Austria, 6020 Site Reference ID/Investigator# 36983 Linz, Austria, 4010 Site Reference ID/Investigator# 27484 Linz, Austria, 4020 Site Reference ID/Investigator# 27485 Rottenmann, Austria, 8786 Site Reference ID/Investigator# 27446 Vienna, Austria, 1030 Site Reference ID/Investigator# 53469 Vienna, Austria, 1090 Site Reference ID/Investigator# 27482 Vienna, Austria, 1130 Site Reference ID/Investigator# 10981 Vienna, Austria, 1220 收起 << | |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.54mL 0.51mL 0.25mL |
12.69mL 2.54mL 1.27mL |
25.39mL 5.08mL 2.54mL |
|
| CAS号 | 364782-34-3 |
| 分子式 | C22H23ClF3N |
| 分子量 | 393.87 |
| SMILES Code | FC(C1=CC(CCCN[C@@H](C2=C3C=CC=CC3=CC=C2)C)=CC=C1)(F)F.[H]Cl |
| MDL No. | MFCD08067750 |
| 别名 | AMG-073 hydrochloride; Cinacalcet (hydrochloride); Mimpara; KRN 1493; AMG 073; Cinacalcet HCl |
| 运输 | 蓝冰 |
| InChI Key | QANQWUQOEJZMLL-PKLMIRHRSA-N |
| Pubchem ID | 156418 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, room temperature |
| 溶解方案 |
DMSO: 50 mg/mL(126.94 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 1 mg/mL(2.54 mM),配合低频超声,并水浴加热至45℃助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1